Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Average Collection Period for the Trailing 12 Months (TTM) ending March 31, 2024

Biomea Fusion Inc Average Collection Period is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The average collection period measures the average number of days it takes for a company to collect payments from its customers. It is calculated by dividing 365 by the ratio of revenue to the average of receivables and other current assets. A lower average collection period indicates a more efficient collection process and better cash flow management, while a higher period may suggest delayed payments and potential liquidity challenges.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email